Do we have to anticoagulated patients with cerebral venous thrombosis?

G Feher, Z Illes, D Hargroves, S Komoly

Research output: Contribution to journalJournal articleResearchpeer-review

Abstract

INTRODUCTION: Cerebral venous thrombosis (CVT) is a rare form of venous thromboembolism (VTE). Although anticoagulation is recommended for the initial and long term treatment with regards to thrombotic risks for patients with CVT, the role of anticogalution has not been fully elucidated. The aim of our literature based review was collect articles showing the benefit of anticoagulation in CVT and gathering the data of follow-up studies focusing on the recurrence of CVT and other thrombotic events.

RESULTS: We have identified 15 follow-up studies studies with 2422 patients . The mean duration of follow up was 37,9 months. Death occured in 6,5% and 76,4 % of the patients had favourable outcome. 85,5 % received initial anticoagulation with ultrafractionated or low molecular weight heparin and 82,1 % received long-term anticoagulation. Recurent CVT occured in 3,7% and other thrombotic event occured in 5,4%. The mentioned studies have led to incoclusive results with regards to the clinical outcome and the presence or absence of anticoagulation.

CONCLUSION: The role of long term anticoagulation should be clarified in randomized multicentre studies as the recurrence rate seems to be low and the outcome of a second event as good as that of the first one irrespective of underlying risk factors.

Original languageEnglish
JournalInternational Angiology
Volume35
Issue number4
Pages (from-to)369-373
ISSN0392-9590
Publication statusPublished - 2016

Fingerprint

Multicenter Studies

Cite this

Feher, G ; Illes, Z ; Hargroves, D ; Komoly, S. / Do we have to anticoagulated patients with cerebral venous thrombosis?. In: International Angiology. 2016 ; Vol. 35, No. 4. pp. 369-373.
@article{3a83dc2923b8402ea38f9efef17263a2,
title = "Do we have to anticoagulated patients with cerebral venous thrombosis?",
abstract = "INTRODUCTION: Cerebral venous thrombosis (CVT) is a rare form of venous thromboembolism (VTE). Although anticoagulation is recommended for the initial and long term treatment with regards to thrombotic risks for patients with CVT, the role of anticogalution has not been fully elucidated. The aim of our literature based review was collect articles showing the benefit of anticoagulation in CVT and gathering the data of follow-up studies focusing on the recurrence of CVT and other thrombotic events.RESULTS: We have identified 15 follow-up studies studies with 2422 patients . The mean duration of follow up was 37,9 months. Death occured in 6,5{\%} and 76,4 {\%} of the patients had favourable outcome. 85,5 {\%} received initial anticoagulation with ultrafractionated or low molecular weight heparin and 82,1 {\%} received long-term anticoagulation. Recurent CVT occured in 3,7{\%} and other thrombotic event occured in 5,4{\%}. The mentioned studies have led to incoclusive results with regards to the clinical outcome and the presence or absence of anticoagulation.CONCLUSION: The role of long term anticoagulation should be clarified in randomized multicentre studies as the recurrence rate seems to be low and the outcome of a second event as good as that of the first one irrespective of underlying risk factors.",
author = "G Feher and Z Illes and D Hargroves and S Komoly",
year = "2016",
language = "English",
volume = "35",
pages = "369--373",
journal = "International Angiology",
issn = "0392-9590",
publisher = "EdizioniMinerva Medica",
number = "4",

}

Feher, G, Illes, Z, Hargroves, D & Komoly, S 2016, 'Do we have to anticoagulated patients with cerebral venous thrombosis?', International Angiology, vol. 35, no. 4, pp. 369-373.

Do we have to anticoagulated patients with cerebral venous thrombosis? / Feher, G; Illes, Z; Hargroves, D; Komoly, S.

In: International Angiology, Vol. 35, No. 4, 2016, p. 369-373.

Research output: Contribution to journalJournal articleResearchpeer-review

TY - JOUR

T1 - Do we have to anticoagulated patients with cerebral venous thrombosis?

AU - Feher, G

AU - Illes, Z

AU - Hargroves, D

AU - Komoly, S

PY - 2016

Y1 - 2016

N2 - INTRODUCTION: Cerebral venous thrombosis (CVT) is a rare form of venous thromboembolism (VTE). Although anticoagulation is recommended for the initial and long term treatment with regards to thrombotic risks for patients with CVT, the role of anticogalution has not been fully elucidated. The aim of our literature based review was collect articles showing the benefit of anticoagulation in CVT and gathering the data of follow-up studies focusing on the recurrence of CVT and other thrombotic events.RESULTS: We have identified 15 follow-up studies studies with 2422 patients . The mean duration of follow up was 37,9 months. Death occured in 6,5% and 76,4 % of the patients had favourable outcome. 85,5 % received initial anticoagulation with ultrafractionated or low molecular weight heparin and 82,1 % received long-term anticoagulation. Recurent CVT occured in 3,7% and other thrombotic event occured in 5,4%. The mentioned studies have led to incoclusive results with regards to the clinical outcome and the presence or absence of anticoagulation.CONCLUSION: The role of long term anticoagulation should be clarified in randomized multicentre studies as the recurrence rate seems to be low and the outcome of a second event as good as that of the first one irrespective of underlying risk factors.

AB - INTRODUCTION: Cerebral venous thrombosis (CVT) is a rare form of venous thromboembolism (VTE). Although anticoagulation is recommended for the initial and long term treatment with regards to thrombotic risks for patients with CVT, the role of anticogalution has not been fully elucidated. The aim of our literature based review was collect articles showing the benefit of anticoagulation in CVT and gathering the data of follow-up studies focusing on the recurrence of CVT and other thrombotic events.RESULTS: We have identified 15 follow-up studies studies with 2422 patients . The mean duration of follow up was 37,9 months. Death occured in 6,5% and 76,4 % of the patients had favourable outcome. 85,5 % received initial anticoagulation with ultrafractionated or low molecular weight heparin and 82,1 % received long-term anticoagulation. Recurent CVT occured in 3,7% and other thrombotic event occured in 5,4%. The mentioned studies have led to incoclusive results with regards to the clinical outcome and the presence or absence of anticoagulation.CONCLUSION: The role of long term anticoagulation should be clarified in randomized multicentre studies as the recurrence rate seems to be low and the outcome of a second event as good as that of the first one irrespective of underlying risk factors.

UR - http://www.ncbi.nlm.nih.gov/pubmed/?term=Do+we+have+to+anticoagulate+patients+with+cerebral+venous+thrombosis%3F&report=medline&format=text

M3 - Journal article

C2 - 26017760

VL - 35

SP - 369

EP - 373

JO - International Angiology

JF - International Angiology

SN - 0392-9590

IS - 4

ER -